Health
FDA Grants Accelerated Approval to First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
Inovio's Voceryq gives adults with a rare, HPV-driven airway disease a new option aimed at cutting repeat surgeries.
Inovio Pharmaceuticals News
All Happy News Company coverage of Inovio Pharmaceuticals: the latest health news, with links to every original source.
Health
FDA Approves Voceryq, the First Plasmid DNA Immunotherapy, for a Rare Airway Disease
Inovio's treatment for recurrent respiratory papillomatosis is cleared under accelerated approval, giving adults a new option beyond repeated surgery.
Got good news? Let's share it.
Publish your impact story, donation, milestone or community launch on Happy News Company from $99. Nonprofits save 25%.